More support for Alertix’ acclaimed research of PrediPet screening. This time from Sweden’s Innovation Agency Vinnova.

Alertix plans to broaden and deepen its clinical documentation to verify initial results from smaller studies, and receives support from Sweden’s Innovation Agency Vinnova (programme Innovative Startups) to conduct clinical verification studies of its veterinary diagnostic biomarker for tumor diseases in dogs.

Predipet has received the innovation award Skapa in Kalmar and will participate as a national finalist in the national SKAPA award ceremony in Stockholm in November.